Abstract
Cangrelor, an intravenous, potent, direct-acting adenosine diphosphate (ADP) receptor antagonist, significantly reduced the composite endpoint of death, myocardial infarction (MI), ischemia-driven revascularization, and stent thrombosis in patients undergoing percutaneous coronary intervention (PCI) with no excess in severe bleeding compared with clopidogrel loading at the time of PCI. This article presents the results of the Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [CHAMPION PHOENIX; Bhatt DL et al. N Engl J Med 2013] in a late-breaking clinical trial.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
